公开(公告)号：US12006275B2

公开(公告)日：2024-06-11

申请号：US17435881

申请日：2020-03-02

申请人： CHEMAPOTHECA, LLC

发明人： Harold Meckler ,  Praveen Suryadevara ,  Marcus Brackeen ,  Darryl Cleary

IPC分类号： C07C209/62 ,  C07C209/86 ,  C07F9/22 ,  C07F9/564 ,  G01N33/94

CPC分类号： C07C209/62 ,  C07C209/86 ,  C07F9/222 ,  C07F9/564 ,  G01N33/946

摘要： This is invention is related to processes for synthesis of levoamphetamine derivatives and novel intermediates thereby, and processes for using the same.

公开(公告)号：US20240002374A1

公开(公告)日：2024-01-04

申请号：US17742169

申请日：2022-05-11

申请人： Genzyme Corporation

发明人： Junkai Liao ,  Mark Munson ,  Zhongli Gao ,  Gregory Hurlbut ,  Sylvie Baltzer ,  Bertrand Vivet ,  Brian Freed ,  Hans Peter Nestler ,  Helen Yeoman ,  Ingrid Mechin ,  Martin Smrcina ,  Nina Ma ,  Sylvain Lebreton ,  Ryan Hartung ,  William Wire ,  Sukanthini Thurairatnam

IPC分类号： C07D417/12 ,  C07D277/52 ,  C07D417/04 ,  C07D417/14 ,  C07F9/22 ,  C07D498/10

CPC分类号： C07D417/12 ,  C07D277/52 ,  C07D498/10 ,  C07D417/14 ,  C07F9/222 ,  C07D417/04

摘要： The invention relates to heteroaryl compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

公开(公告)号：US20230012655A1

公开(公告)日：2023-01-19

申请号：US17589864

申请日：2022-01-31

申请人： Tufts University

发明人： Philip G. Haydon ,  Jinbo Lee

IPC分类号： A61K31/7072 ,  A61K31/7052 ,  A61K31/706 ,  A61K31/7068 ,  A61K31/7064 ,  A61K31/7042 ,  C07D405/14 ,  C07D413/14 ,  C07D405/04 ,  C07H19/067 ,  C07F9/6558 ,  C07F9/6574 ,  C07F9/09 ,  C07F9/22 ,  C07H19/06 ,  A61K9/00

摘要： This disclosure relates to the use of uridine diphosphate (UDP) derivatives, salts and/or prodrugs thereof for the treatment of inflammatory conditions (e.g., psoriasis) and glaucoma, to prodrugs of UDP derivatives, compositions comprising therapeutically effective amounts of those prodrugs of the UDP derivatives and methods of using those prodrugs for treating various disorders including, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease) and traumatic CNS injury, pain, Down Syndrome (DS), glaucoma, and inflammatory conditions, e.g., psoriasis and rheumatoid arthritis.

公开(公告)号：US11518994B2

公开(公告)日：2022-12-06

申请号：US16073998

申请日：2017-01-30

申请人： BONAC CORPORATION

发明人： Eriko Aoki ,  Tadaaki Ohgi ,  Takashi Kinoshita

IPC分类号： C12N15/11 ,  C12N9/22 ,  C12N15/90 ,  C07C229/04 ,  C07C229/34 ,  C12N15/113 ,  C07F9/22 ,  C40B50/06

摘要： The invention provides an artificial sgRNA and a CRISPR/Cas9 system by combining the artificial sgRNA and Cas9. Activity of the sgRNA can be retained even when a nucleotide linker region for forming a single strand by linking the 3′-terminal of crRNA and the 5′-terminal of tracrRNA in sgRNA is substituted with an amino acid derivative linker, when the linker region existing between stem-loop 1 and stem-loop 2 of tracrRNA and/or the loop portion of stem-loop 2 are/is substituted with an amino acid derivative linker, or when an amino acid derivative linker is added/inserted into the vicinity of the 5′-terminal and/or the 3′-terminal of sgRNA. Stability in vivo can be improved by introducing one or more amino acid derivative linkers into the sgRNA.

公开(公告)号：US20220162153A1

公开(公告)日：2022-05-26

申请号：US17435881

申请日：2020-03-02

申请人： CHEMAPOTHECA, LLC

发明人： HAROLD MECKLER ,  PRAVEEN SURYADEVARA ,  MARCUS BRACKEEN ,  DARRYL CLEARY

IPC分类号： C07C209/62 ,  C07F9/22 ,  C07F9/564 ,  C07C209/86 ,  G01N33/94

摘要： This is invention is related to processes for synthesis of levoamphetamine derivatives and novel intermediates thereby, and processes for using the same.

公开(公告)号：US20210380496A1

公开(公告)日：2021-12-09

申请号：US17404932

申请日：2021-08-17

申请人： World Source Enterprises, LLC

发明人： Gary David McKnight ,  David Bruce Parker ,  Yang Zehni ,  Ray Perkins ,  Wei Xu

IPC分类号： C05C9/00 ,  C09K15/28 ,  C05C9/02 ,  C07F9/22 ,  C05G3/90 ,  C05G5/30 ,  C05G5/23

摘要： An improved solvent system for the formulation and application of N-alkyl thiophosphoric triamide urease inhibitors. These formulations provide safety and performance benefits relative to existing alternatives and enable storage, transport and subsequent coating or blending with urea based or organic based fertilizers. These formulations are comprised primarily of environmentally friendly aprotic and protic solvents (particularly dimethyl sulfoxide and alcohols/polyols) to stabilize the urease inhibitor.

公开(公告)号：US11124462B1

公开(公告)日：2021-09-21

申请号：US16552588

申请日：2019-08-27

申请人： Hocking International Laboratories, LLC

发明人： Douglas Hocking ,  Robert Munion

IPC分类号： C05G3/90 ,  C05C3/00 ,  C05C1/00 ,  C05C9/00 ,  C05G5/20 ,  C07F9/22 ,  C05G3/00

摘要： Compositions include dicyandiamide (DCD), N—(N-butyl) Thiophosphoric Triamide (NBPT), and styrene-maleic anhydride copolymer in a solution. Agricultural fertilizer compositions contain the DCD, NBPT and styrene-maleic anhydride copolymer composition in combination with a fertilizer.

公开(公告)号：US11072567B2

公开(公告)日：2021-07-27

申请号：US15767446

申请日：2016-11-10

申请人： YARA INTERNATIONAL ASA

发明人： Francois Ledoux ,  Filip Colpaert ,  Ruud Van Belzen

IPC分类号： C05G3/90 ,  C05C9/00 ,  C07F9/22

摘要： The invention relates to a solid, particulate, urea-based blend composition comprising a urea-based compound in particulate form, one or more components in particulate form, selected from the group of nitrates, phosphates, sulphates and chlorides, and a urease inhibitor of the type phosphoric triamide, in particular N-(n-butyl) thiophosphoric triamide (nBTPT), wherein the urea-based blend composition is further characterized in that it comprises one or more reactive alkaline or alkaline-forming inorganic or organic compounds. The composition according to the invention has been stabilized against the degradation of a urease inhibitor of the type phosphoric triamide, in particular N-(n-butyl) thiophosphoric triamide (nBTPT). The invention further relates to a method for the manufacture of the claimed solid, particulate, urea-based blend composition.

公开(公告)号：US11028111B2

公开(公告)日：2021-06-08

申请号：US16626934

申请日：2018-08-15

申请人： Xi' An Biocare Pharma Ltd.

发明人： Guoqin Fu ,  Wei Ding ,  Bo Yin ,  Chao Yang ,  Cuiqin Wang ,  Yong Dou ,  Ruiling Wang

IPC分类号： C07F9/6574 ,  A61P1/16 ,  A61P9/12 ,  C07F9/22

摘要： Provided are a compound for treating metabolic diseases having the structure as shown in formula (I) or formula (II), or a racemate, stereoisomer, geometric isomer, tautomer, solvate, hydrate, metabolite, pharmaceutically acceptable salt or prodrug thereof. The compound is an activator of FXR and/or a TGR5 receptor, and thus has the activity of activating FXR and/or a TGR5 receptor, and can be used in the preparation of drugs for treating chronic liver diseases, metabolic diseases or portal hypertension.

公开(公告)号：US11001697B2

公开(公告)日：2021-05-11

申请号：US16362957

申请日：2019-03-25

申请人： International Business Machines Corporation

发明人： Scott B. King ,  Brandon M. Kobilka ,  Joseph Kuczynski ,  Jason T. Wertz

IPC分类号： C07D211/58 ,  C07D211/44 ,  C08K5/00 ,  C07C211/09 ,  C07F9/6558 ,  C07F9/09 ,  C07F9/59 ,  C07F9/22

摘要： A process a process of forming a non-halogenated flame retardant (FR) hindered amine light stabilizer (HALS) cross-linker is disclosed. The process includes forming a mixture that includes a first molecule having a hindered amine group. The first molecule corresponds to a functionalized 2,2,6,6-tetramethylpiperidine (TMP) molecule. The process also includes forming the non-halogenated FR HALS cross-linker via a chemical reaction of the first molecule a second molecule. The second molecule includes a phosphoryl group, a chloride group, and at least one cross-linkable (CL) moiety.